Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Metastatic Bladder Urothelial Carcinoma 1Lymphoma 1Kidney Failure, Chronic 1Extensive Stage Small Cell Lung Carcinoma 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Molecular Imaging 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Coronary Artery Disease × Immunoglobulin G × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡